Loading...
Derniers dépôts
-
Oluwasayo Loto, Izabella Zahradnik, Amelia Maia Leite, Ludovic de Marzi, Dominique Tromson, et al.. Simultaneousmeasurements of dose and microdosimetric spectra in a clinical proton beam using a scCVD diamond membrane microdosimeter. Sensors, 2021, 21 (4), pp.1314. ⟨10.3390/s21041314⟩. ⟨cea-04551117⟩
-
Karin Kast, Esther M John, John L Hopper, Nadine Andrieu, Catherine Noguès, et al.. Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium. Breast Cancer Research, 2023, 25 (1), pp.72. ⟨10.1186/s13058-023-01673-w⟩. ⟨inserm-04546076⟩
-
Mark van Barele, Delal Akdeniz, Bernadette a M Heemskerk-Gerritsen, Nadine Andrieu, Catherine Noguès, et al.. Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation. JNCI: Journal of the National Cancer Institute, 2024, 115, pp.1318 - 1328. ⟨10.1093/jnci/djad116⟩. ⟨inserm-04545755⟩
-
Xavier Sastre-Garau, Mamadou Diop, Fernando Martin, Gilles Dolivet, Frédéric Marchal, et al.. A NGS-based blood test for the diagnosis of invasive HPV-associated carcinomas with extensive viral genomic characterization. Clinical Cancer Research, 2021, 27 (19), pp.5307-5316. ⟨10.1158/1078-0432.ccr-21-0293⟩. ⟨hal-04543989⟩
-
Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
-
Laurence Brugières, Nathalie Cozic, Roch Houot, Charlotte Rigaud, David Sibon, et al.. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS-crizotinib trial. European Journal of Cancer, 2023, 191, pp.112984. ⟨10.1016/j.ejca.2023.112984⟩. ⟨hal-04228222⟩